Side-by-side · Research reference

5-Amino-1MQvsBPC-157

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft8/38 cited

BPhase 2Reviewed9/53 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

01Mechanism of Action

Parameter

5-Amino-1MQ

BPC-157

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014 Sikiric 2018

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Feedback intact?

—

No known endogenous receptor; mechanism still under investigation

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

BPC-157

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

Frequency

Once daily, fasted

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Lower / starter dose

50 mg / day

200 mcg / day

Conservative starter for new users.

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Duration

8–12 weeks per cycle

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

Form

Oral capsule

—

Timing

Morning fasted preferred

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

Half-life

Hours (estimated; no human PK published)

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

Reconstitution

—

Bacteriostatic water, 1–2 mL

04Side Effects & Safety

Parameter

5-Amino-1MQ

BPC-157

GI symptoms

Mild nausea (anecdotal)

None reported in PL-14736 Phase 2

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

Unknown beyond Phase 2 trial duration

Cancer risk

Unclear — NNMT also studied in oncology contexts

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

Pregnancy / OB

Avoid

Avoid — insufficient safety data

Drug interactions

Theoretical with niacin / B-vitamin supplements

None established

Injection site reaction

—

Mild irritation (anecdotal)

Cardiovascular

—

Not reported

Antibody formation

—

No data (no long-term human trials)

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

05Administration Protocol

Parameter

5-Amino-1MQ

BPC-157

1. Form

Oral capsule. No injection.

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

2. Administration

Take with water, fasted preferred.

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

3. Timing

Morning fasted.

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Caveat

Monitor B-vitamin status with chronic use.

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

06Stack Synergy

5-Amino-1MQ

— no documented stacks

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration